Compare LITE & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITE | INSM |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 23.0B |
| IPO Year | 2015 | 2000 |
| Metric | LITE | INSM |
|---|---|---|
| Price | $926.18 | $104.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $645.43 | $201.17 |
| AVG Volume (30 Days) | ★ 5.3M | 4.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.56 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $1,247,700,000.00 | N/A |
| Revenue This Year | $79.88 | $182.31 |
| Revenue Next Year | $66.61 | $65.19 |
| P/E Ratio | $362.16 | ★ N/A |
| Revenue Growth | ★ 24.57 | N/A |
| 52 Week Low | $80.39 | $70.57 |
| 52 Week High | $1,085.68 | $212.75 |
| Indicator | LITE | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 35.54 |
| Support Level | $820.17 | $98.90 |
| Resistance Level | $942.75 | $166.81 |
| Average True Range (ATR) | 80.01 | 3.90 |
| MACD | -3.12 | 0.82 |
| Stochastic Oscillator | 50.52 | 30.97 |
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.